Form 4: Guardant Health Chief Medical Officer Reports RSU Vesting and Tax-Related Share Sale

Guardant Health's Chief Medical Officer, Craig Eagle, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations, resulting in a net increase in his direct beneficial ownership.

Summary

• Craig Eagle, Chief Medical Officer of Guardant Health, Inc. (GH), reported changes in his beneficial ownership of common stock.
• On June 15, 2025, Mr. Eagle acquired 1,402 shares of common stock through the vesting of an installment of his restricted stock units (RSUs) at a price of $0.
• Concurrently, 711 shares were disposed of at a price of $49.29 to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Mr. Eagle's direct beneficial ownership of Guardant Health common stock stands at 35,124 shares.
• The RSU award was originally granted on June 9, 2023, with 33% vesting on June 15, 2024, and the remaining 67% scheduled to vest in equal quarterly installments over the subsequent two-year period.
• Additionally, Mr. Eagle holds 5,608 unvested Restricted Stock Units.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine insider transaction (RSU vesting and tax sale), which is expected. The net increase in the executive's direct ownership is a minor positive, indicating continued alignment, but the transaction itself is not a strong indicator of company performance or future prospects.

Positives

• The Chief Medical Officer's direct beneficial ownership of Guardant Health common stock increased by 691 shares as a result of the RSU vesting and subsequent tax-related sale, indicating continued equity alignment with shareholders.
• The transaction reflects a standard vesting and tax withholding process for executive compensation, demonstrating a normal course of business operation.

Negatives

• No specific negative aspects are apparent from this routine insider transaction filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The filing indicates future vesting of the remaining 67% of the Restricted Stock Units in equal quarterly installments over a two-year period following June 15, 2024.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically the vesting of executive compensation. It does not provide broader industry context or trends, as its scope is limited to individual beneficial ownership changes within Guardant Health, Inc.

Comparison to Industry Standards

• This Form 4 filing details a standard executive compensation event (RSU vesting and tax-related share disposition).
• Such transactions are common across publicly traded companies in the biotechnology and healthcare sectors, including peers like Exact Sciences Corp. (EXAS) or Illumina, Inc. (ILMN), where executives frequently receive equity-based compensation that vests over time.
• The 'sell to cover' mechanism for tax obligations is a widely accepted and routine practice for RSU vesting across all industries, not specific to healthcare.

Stakeholder Impact

• Shareholders: The net increase in the Chief Medical Officer's direct share ownership aligns his interests further with shareholders, potentially signaling confidence in the company's long-term prospects.
• Employees: The RSU vesting demonstrates the company's commitment to its equity compensation plans, which can be a positive for employee retention and motivation.

Next Steps

• Remaining 67% of the Restricted Stock Units will vest in equal quarterly installments over the two-year period following June 15, 2024.

Key Dates

Recommendation

Keywords

Guardant Health, GH, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Craig Eagle, Chief Medical Officer, Share Ownership, Tax Withholding